DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vorinostat
Vorinostat
An Overview of the Role of Hdacs in Cancer Immunotherapy
North American Brain Tumor Consortium Study 04-03
Standard Oncology Criteria C16154-A
Broad-Spectrum HDAC Inhibitors Promote Autophagy Through FOXO Transcription Factors in Neuroblastoma
Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
Targeted Therapy–Based Combination Treatment in Rhabdomyosarcoma Anke E.M
Temozolomide Use in IDH-Mutant Gliomas
Intravesical Treatment with Vorinostat Can Prevent Tumor Progression in MNU Induced Bladder Cancer
Cip1 and P27kip1 in Hdaci-Mediated Tumor Cell Death and Cell Cycle Arrest in the Em-Myc Model of B-Cell Lymphoma
The Effects of Taxanes, Vorinostat and Doxorubicin on Growth And
Solubilization of Vorinostat by Cyclodextrins
ZOLINZA Safely and Effectively
Cancer Drug Costs for a Month of Treatment at Initial Food
Novel Drugs for Older Patients with Acute Myeloid Leukemia
ZOLINZA® (Vorinostat)
2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
Top View
Romidepsin in the Treatment of Hematologic Malignancies
FDA Approval: Belinostat for the Treatment of Patients with Relapsed Or Refractory
Patient-Assistance-Reimbursement-Guide-2019.Pdf
Vorinostat Combined with Dnmti Epigenetically Controls the Proliferation of Lung Cancer Cells A549
Emerging Drugs for Prostate Cancer
Chemogenomic Screening Identifies the Hsp70 Co-Chaperone HDJ2 As
Phase I/II Intra-Patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma, Or Leukemia Cornelis M
Phase 1/1B Pembrolizumab Plus Vorinostat in Advanced NSCLC
The Inhibitor of Histone Deacetylases Sodium Butyrate Enhances the Cytotoxicity of Mitomycin C
Low Concentrations of Vorinostat Decrease EB1 Expression in GBM Cells and Affect Microtubule Dynamics, Cell Survival and Migration
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Zolinza (Vorinostat) Usage in the Treatment of Cancer, Including FDA Approved Indications, and Off-Label Indications
Nanofiber-Coated Stent for Inhibition of Cholangiocarcinoma Cells
The Histone Deacetylase Inhibitor Vorinostat Induces Calreticulin
Targeting HDAC with a Novel Inhibitor Effectively Reverses Paclitaxel Resistance in Non-Small Cell Lung Cancer Via Multiple Mechanisms
Histone Deacetylase Inhibitor Induces DNA Damage, Which Normal but Not Transformed Cells Can Repair
Strategies to Circumvent the T315I Gatekeeper Mutation in the Bcr-Abl Tyrosine Kinase
Early Stage Treatment Options Theresa Pacheco, Md